SILVER SPRING, MD. (EGMN) - The data on the kinase inhibitor axitinib support its approval as a second-line treatment for advanced renal cell carcinoma, a Food and Drug Administration advisory panel unanimously agreed at a Dec. 7 meeting.At the meeting, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 13-0 that axitinib has a favorable risk-benefit profile for treating patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy, based on the results of...